Contact Us | Log In
Sensex: 33136.2 +139.40 Gold: Rs.30321.00
Nifty: 10155.2 +30.90 Silver: Rs.38372.00
Pharmaceuticals Q2FY18 Results Review -
Pharmaceuticals Q2FY18 Results Review
Prabhudas Lilladher | Published: 28 Nov, 2017  | Source :
  • Generics continue to be under pricing pressure and see higher competitive intensity   

  • Average price erosion were 2-4% QoQ and 8-12% YoY

  • Specialty portfolio sales of DRL and SUNP continues to be at nascent stage

  • Consensus guidance is price erosion continues to be regular phenomenon

  • Benefits from key launches: gRenvela tabs/PFOS (Aurobindo), gStrattera (Aurobindo, Glenmark), gProtonix-IV (Inj-Aurobindo), gLipodox (DRL), gLialda (Cadila), gNitrostat (Glenmark)

           Link to the PDF

About Prabhudas Lilladher

Prabhudas Lilladher has a nationwide distribution network, consisting of branches, franchisees and associates, providing a comprehensive gamut of financial services in the Institutional and Retail domain. Their services includes Equity, derivatives; margin funding, mutual funds, PMS, IPOs and online trading.


For more information please write in to

Disclaimer: The author has taken due care and caution to compile and analyse the data. The opinions expressed above are only the views of the author, and not a recommendation to buy or sell. Neither the author nor accept any liability whatsoever arising from the use of any of the above contents.